Incyte (NASDAQ:INCY) Earns Buy Rating from HC Wainwright

robot
Abstract generation in progress

HC Wainwright has reiterated a “Buy” rating for Incyte (NASDAQ:INCY), setting a price target of $135, which suggests a 49% upside. While analysts are mixed, with a consensus “Hold” rating and an average target of $103.44, the biopharmaceutical company recently reported strong revenue growth, exceeding expectations despite an EPS miss. Incyte is trading around $90.62, with a market cap of $18.0 billion and a P/E ratio of 14.14.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin